Officials move to strip Calif. doctor of license
August 31st, 2010 by admin
Posted in Oxycontin | No Comments »
August 31st, 2010 by admin
Posted in Oxycontin | No Comments »
August 30th, 2010 by admin
According to figures released by Centers for Disease Control and Prevention, fatal overdoses of opiates–including OxyContin–outnumber those caused by other drugs. In Indiana, the that compared to the national average, the abuse of prescription drugs is climbing higher faster than that of illegal drugs. In 2008, the use of OxyContin alone had increased by 712 percent in the state. One major cause for the change is that unlike “street drugs” such as cocaine and marijuana which are smuggled in from other countries, prescription narcotics are readily available at local pharmacies.
“People have the perception that it’s a prescription drug, it’s approved by the FDA, so it’s safer than crack or whatever,” said Mary Hendrickson, director of quality/regulatory affairs for GENCO Pharmaceutical Services in Milwaukee.
To read about the national trend of increased prescription drug abuse, .
Posted in Oxycontin | No Comments »
August 29th, 2010 by admin
Now. Or I swear to christ I’ll kill every hooker in this cabana.
That is all.
Posted in Oxycontin | No Comments »
August 29th, 2010 by admin
Facing the highest per capita usage of narcotics in the world, and double the rate of abuse than the rest of the country, the province of Ontario, Canada is implementing a prescription drug monitoring program similar to those already in place in the U.S. Ontario has seen the use of prescription oxycodone increase 900 percent since 1991, claiming more deaths than HIV each year, . According to a study published in the Canadian Medical Association Journal late last year, the death toll has increased dramatically since the new slow-release version of OxyContin hit the market—supposedly a version less prone to abuse.
To read more about the new version of slow-release OxyContin, .
Find out more about prescription drug monitoring programs in the U.S.
Posted in Oxycontin | No Comments »
August 27th, 2010 by admin
An upswing the use of heroin in small towns can be linked to the growing abuse of prescription drugs, such as OxyContin, and the high price associated with them, reports . Also an opiate, heroin is often used as a substitute drug for oxy abusers as it costs significantly less and can be easier to obtain. As an example, drastic growth in drug-related crimes in the small town of Snomish, Wash. including a pharmacy being robbed of $50,000 worth of OxyContin.
Read about the 400% increase in prescription pill abuse
Posted in Oxycontin | No Comments »
August 26th, 2010 by admin

(Photo by Joe Raedle/Getty Images)
Startling numbers are out about the number of Americans who admit to drinking and driving. Giving sight to the blind is more of a reality now by using the properties of one word: plastic. Get details on this and a new drug that shrinks skin cancer tumors in today’s Health Notes.
Posted in Oxycontin | No Comments »
August 26th, 2010 by admin
Through an updated electronic monitoring system, Mass. doctors will keep closer tabs on potential prescription drug abuse, including OxyContin–the abuse of which is a particular problem in the state. , the law will limit doctors prescribing unnecessary drugs, increases the number of drugs that are monitored, and report when patients are receiving the same prescription from multiple sources, among other changes. At least 9,000 Mass. residents are suspected of engaging in “doctor shopping” annually, . , the state joins 34 others in the U.S. with existing prescription monitoring programs.
Decisions leading up to Mass. prescription monitoring program can be found .
Reports on opiate abuse in Mass can be read
Read about Oregon’s implementation of the program .
Posted in Oxycontin | No Comments »
August 25th, 2010 by admin
Australian company Mundipharma fights patents on generic forms of oxycodone, . A generic version of the drug would drastically cut the pharmaceutical company’s profits of OxyContin–the highest selling opiate in Australia with reported sales of $42 million in 2009. A similar situation is echoed with the U.S. manufacturer of OxyContin, Purdue Pharma LP, which recently submitted a new patent for the . The new patent ensures other companies will not be able to create generic forms of oxycodone,
Posted in Oxycontin | No Comments »
August 24th, 2010 by admin
My daughter is in the capable hands of a wonderful Detox facility. My daughter hugged me and cried her eyes out as she said goodbye, asking me to promise her that I will be there when she gets out.
Last night was brutal. My daughter was in my bed but not sleeping, more like sleep wrestling. I couldn’t believe how many times she sat up, screamed in pain, cuddled up to me and asked me to hold her tightly then followed by another scream, sitting up, twisting in bed, rolling over and over and over, kicking covers off, pulling them back on, lights off, lights on, hot then cold, awake and then asleep. Withdrawals are terrifying!!
I feel so relieved today because she is in much more capable hands. My husband and I are looking into Al Anon (are there meetings for co-dependants of NA?). We both feel like our whole family needs to go to meetings so we are speaking the same language when she gets out. We are also looking into a Rehab Clinic for her following the Detox.
I am exhausted…but I wanted to reach out and thank everyone for their support and kind words. I rely upon all of you so much now, so please know how much I love your comments and honest feedback.
xoxo
Posted in Oxycontin | No Comments »
August 24th, 2010 by admin
| Efficacy of SMR-Beta Neurofeedback for Attentional Processes
David A. Kaiser and Siegfried Othmer November 1997
The apparent diversity of disorders impacted by SMR-beta neurofeedback training suggests a commonality of mechanisms for these conditions, a fact that should be addressed by any theory that attempts to identify the therapeutic mechanism of SMR-beta neurofeedback. Sterman (1982) proposed that SMR neurofeedback may restore regulated function of thalamocortical mechanisms associated with arousal. In particular, abnormal sensorimotor arousal or excitability may interfere with higher cognitive functions in a resource-limited competive model (Sterman, 1996). Abarbanel (1995) formulated a similar model of self-regulation in which attentional processing were modulated by thalamocortical and limbic circuitry. In his model long-term potentiation was responsible for any functional permanence associated with training. Both models presume SMR-beta neurofeedback impacts functions that modulate arousal (Sterman, 1982; Abarbanel, 1995). Both models readily address the symptomatology and possible mechanisms of ADHD and epilepsy. The primary symptoms of ADHD, inattention, impulsivity, or hyperactivity, are associated with decreased arousal in frontal cortex and subcortical regions (Zametkin et al., 1990; Mann, Lubar, Zimmerman, Miller, & Muenchen, 1991). The cortical hyperexcitability associated with epilepsy may reflect an arousal dyfunction, possibly due to a loss of integrity in the thalamic gating mechanism (Sterman, 1982). In addition to motor or vocal tics, sufferers of Tourette’s Syndrome often exhibit somnambulism, night terrors, and other disorders of arousal (Barabas, Matthews, & Ferrari, 1984). Attentional processes in particular appear to be uniquely sensitive to problems of arousal, and thus they serve to be a good measure of effectiveness in restoring such functions. The Test of Variables of Attention (TOVA) is a continuous performance task that assesses attentional processes relative to a normative database. The TOVA provides a quantifiable measure of effectiveness of SMR and beta biofeedback training for improving specific attentional properties such as impulse control and response consistency. The lack of test-retest practice effects, the use of language-independent nonverbal stimuli, and an extended test length (22.5 min), all make the TOVA especially useful in evaluating treatment effects in an ADHD, learning disabled, or like population (Greenberg, 1987). The purpose of the present study is to evaluate the efficacy of SMR-beta neurofeedback for children and adults suffering from attentional problems as measured by the TOVA. David A. Kaiser and Siegfried Othmer Subjects
Training consisted of 30 min of visual and auditory feedback on the instrument, within a 45-min contact hour. Visual feedback was provided by a variety of means which map the EEG amplitude in the reward and inhibit bands into the brightness, size, and/or velocity of objects on a computer monitor. Most commonly, information about the amplitude of signals in each of the bands was given independently. Alternatively, the subject was simply be notified that an inhibit threshold was exceeded by the withholding of the conventional reward. When all reward conditions were satisfied for a minimum of 0.5 s, an auditory beep and visual incentive (e.g., highway stripe, star in sky) was provided as reinforcement. The visual feedback signal was occasionally complemented with direct tactile and auditory feedback of EEG amplitude in the reward band. Subjects were evaluated prior to training and after approximately 20 sessions. Those subjects who were further treated were retested after approximately 40 training sessions. Most subjects completed or discontinued training after 20 sessions (mean 24.1, range 18 to 61 sessions). A Huynh-Feldt correction for degrees of freedom was applied to all interactions to counter potential nonsphericity of the four dependent measures. When an interaction of condition (treatment by dependent measures) was significant at the .01 level, planned comparison t-tests were used to evaluate differences for each dependent measure. The Bonferroni correction for multiple tests was consequently applied to planned comparisons. RESULTS
EEG biofeedback training produced significant improvement in inattention scores; F (1,323)= 38.678, p <.001; impulsivity scores, F (1,323)= 191.266, p <.001; and variability of response time, F (1,323)= 32.175, p <.001. Results are even more dramatic when individual data are observed. As can be seen in Figure 1, only a handful of subjects demonstrated declines in impulsivity scores while the majority improved greatly and in proportion to pre-treatment values. Improvement extended above and beyond the normal range for many individuals.
Figure 1. Pre- and post-treatment TOVA impulsivity standard scores for 530 children, adolescents, and adults. Each line segment represents a single subject’s change from pre-training to post-training scores. The data are sorted by pre-training score. Improvement is indicated when the line segment rises above the pre-training value. Those subjects with pre-treatment impulsivity scores less than two standard deviations below the mean (i.e., scores of 70 and below) improved more than 25 points in measures of inattention, F(1,92)=97.414, p<.001; and impulsivity, F(1,79)=107.451, p<.001. Improvement was less marked but still impressive in response time, F(1,60)=15.587, p<.001; and response variability, F(1,110)=80.249, p<.001 (see Figure 2). In all, EEG biofeedback training produced clinically significant improvement (i.e., half a standard deviation increase or more on one or more measures), in 75 % of all subjects, a value comparable to the approximately 70% response rate of psychostimulants (Cantwell, 1994; Barkley, 1990).
Figure 2. Pre- and post-treatment TOVA standard scores for all four dependent measures for subjects with pre-treatment deficits of two standard deviation or more below the mean. Sixty-two subjects underwent an additional period of training after 20 sessions were completed. Understandably, these were individuals who had achieved only modest progress in 20 sessions. Impulsivity was found to improve from pre-treatment levels after 20 sessions and then continued to improve after 40 sessions. Response variability exhibited significant improvement only after 40 training sessions were completed (see Figure 3).
Figure 3. TOVA standard scores for 62 subjects at pre- treatment, METHOD David A. Kaiser and Siegfried Othmer Page 4 of 5
Malone, Kershner, and Swanson (1994) proposed a neurochemical model to explain medical effects on ADHD, a model which holds promise for understanding the efficacy of EEG biofeedback according to the present protocols. Malone et al. (1994) elaborate a bi-hemispheric model of regulation of attention and arousal by Tucker and Williamson (1984). In this model, the dopaminergic system, linked to left hemisphere function, is involved in maintenance of tonic activation, of sustained attentional activity, sequencing, and motor planning; whereas the norepinephrine system, linked to right hemisphere function, is involved in phasic arousal, orientation to novelty, alertness, and shifts of attention in general. ADHD is postulated to result from dysregulation in this asymmetric neural control system for attention and arousal. This may consist of a failure of bihemispheric coordination of attentional processes, in particular due to lack of left hemisphere inhibitory control over the right hemisphere. ADHD is seen as generally characterized by dopamine-mediated under-activation at the left frontal cortical region, concurrent with norepinephrine-mediated overarousal at the right parietal region. Stimulant medication such as with methylphenidate is seen as impacting on both the dopamine and norepinephrine systems so as to restore them to regulatory balance. The present study does not explicitly confirm the validity of this model, since the data were not derived by random assignment, and since subjects were not treated with only a single protocol. Moreover, the presence of comorbidities such as Tourette Syndrome, minor traumatic brain injury, Conduct Disorder, anxiety or depression, in our sample population has their own implications for protocol selection and thus the outcome for TOVA measures were often mixed, as shown in Figure 1. Declines in impulsivity measures were obtained in several instances. However, EEG biofeedback is the only intervention for ADHD which involves explicit hemispheric localization, and thus is specially suited for evaluating the Malone model. Future research on the specificity of EEG biofeedback protocols should shed further light on the mechanisms involved. |
||||||||||||||||
Posted in Oxycontin | No Comments »